AU2013235487B2 - Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines - Google Patents

Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines Download PDF

Info

Publication number
AU2013235487B2
AU2013235487B2 AU2013235487A AU2013235487A AU2013235487B2 AU 2013235487 B2 AU2013235487 B2 AU 2013235487B2 AU 2013235487 A AU2013235487 A AU 2013235487A AU 2013235487 A AU2013235487 A AU 2013235487A AU 2013235487 B2 AU2013235487 B2 AU 2013235487B2
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
group
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013235487A
Other languages
English (en)
Other versions
AU2013235487A1 (en
Inventor
Joseph Fraser Glickman
Ouathek Ouerfelli
Elissaveta PETROVA
Marilyn D. RESH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Memorial Sloan Kettering Cancer Center
Original Assignee
Rockefeller University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University, Memorial Sloan Kettering Cancer Center filed Critical Rockefeller University
Publication of AU2013235487A1 publication Critical patent/AU2013235487A1/en
Application granted granted Critical
Publication of AU2013235487B2 publication Critical patent/AU2013235487B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2013235487A 2012-03-23 2013-03-14 Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines Ceased AU2013235487B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614954P 2012-03-23 2012-03-23
US61/614,954 2012-03-23
PCT/US2013/031311 WO2013142253A2 (en) 2012-03-23 2013-03-14 TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-c]PYRIDINES

Publications (2)

Publication Number Publication Date
AU2013235487A1 AU2013235487A1 (en) 2014-10-09
AU2013235487B2 true AU2013235487B2 (en) 2017-09-07

Family

ID=49223442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013235487A Ceased AU2013235487B2 (en) 2012-03-23 2013-03-14 Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines

Country Status (7)

Country Link
US (3) US9242994B2 (enExample)
EP (1) EP2828267B1 (enExample)
JP (1) JP6117334B2 (enExample)
CN (1) CN104364257B (enExample)
AU (1) AU2013235487B2 (enExample)
CA (1) CA2868356C (enExample)
WO (1) WO2013142253A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013235487B2 (en) * 2012-03-23 2017-09-07 Memorial Sloan-Kettering Cancer Center Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
WO2017218874A1 (en) * 2016-06-16 2017-12-21 Memorial Sloan-Kettering Cancer Center Hedgehog acyltransferase inhibitors and uses thereof
EP4135698A4 (en) * 2020-04-17 2024-08-14 The Trustees of Indiana University SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS
EP4727553A2 (en) 2023-06-13 2026-04-22 The Trustees of Indiana University Small molecule antiviral drug treatment for human papillomavirus infections
WO2025153715A1 (en) * 2024-01-19 2025-07-24 Scenic Biotech Bv Heterocyclic pla2g15 inhibitors and their use in therapy, in the treatment of diseases characterized by lysosomal dysregulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197864A1 (en) * 2008-02-06 2009-08-06 Osi Pharmaceuticals, Inc. Furo- and Thieno [3,2-c] Pyridines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2315274A1 (fr) 1975-06-27 1977-01-21 Parcor Nouveaux derives de la thieno (2,3-c) pyridine, leur preparation et leurs applications
US4749692A (en) 1977-06-22 1988-06-07 Sanofi, S.A. Therapeutic compositions having anti-thrombotic and anti-blood-platelet-aggregating activity
EP0973778A1 (en) * 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
PL2149560T3 (pl) * 2007-05-22 2015-10-30 Astellas Pharma Inc 1-podstawiony związek tetrahydroizochinolinowy
WO2009073203A1 (en) 2007-12-04 2009-06-11 Amgen Inc. Trp-m8 receptor ligands and their use in treatments
TW200944530A (en) * 2008-04-09 2009-11-01 Gruenenthal Chemie Substituted sulfonamide derivatives
DK2350093T3 (da) * 2008-10-24 2012-11-12 Gruenenthal Gmbh Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens.
BRPI1009287A2 (pt) 2009-03-05 2019-09-24 Astellas Pharma Inc composto de quinoxalina
EP2286808A1 (en) 2009-08-18 2011-02-23 Rheinische Friedrich-Wilhelms Universität Cytohesin inhibitors
DE102010013716A1 (de) 2010-03-31 2011-10-06 Rheinische Friedrich-Wilhelms-Universität Bonn Körperschaft des öffentlichen Rechts Verwendung von Cytohesin-Inhibitoren
AU2013235487B2 (en) * 2012-03-23 2017-09-07 Memorial Sloan-Kettering Cancer Center Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197864A1 (en) * 2008-02-06 2009-08-06 Osi Pharmaceuticals, Inc. Furo- and Thieno [3,2-c] Pyridines

Also Published As

Publication number Publication date
CN104364257B (zh) 2017-03-01
HK1207367A1 (en) 2016-01-29
US20150105419A1 (en) 2015-04-16
EP2828267A2 (en) 2015-01-28
JP2015512399A (ja) 2015-04-27
US9242994B2 (en) 2016-01-26
WO2013142253A2 (en) 2013-09-26
JP6117334B2 (ja) 2017-04-19
WO2013142253A3 (en) 2013-11-14
US20160136142A1 (en) 2016-05-19
EP2828267B1 (en) 2019-10-30
CA2868356C (en) 2020-06-23
CN104364257A (zh) 2015-02-18
US9943507B2 (en) 2018-04-17
AU2013235487A1 (en) 2014-10-09
EP2828267A4 (en) 2015-10-28
US20170252328A1 (en) 2017-09-07
CA2868356A1 (en) 2013-09-26
US9597320B2 (en) 2017-03-21

Similar Documents

Publication Publication Date Title
TWI871397B (zh) Ｋｒａｓ突變蛋白抑制劑
JP6718541B2 (ja) セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
US9943507B2 (en) Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
KR102189529B1 (ko) 키누레닌 경로의 억제제
CN102083831B (zh) 用作aurora激酶抑制剂的萘啶酮
RS53831B1 (sr) Pirazolohinolin derivati kao inhibitori dnk-pk
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
KR101960107B1 (ko) 통증의 치료를 위한 ４,５에이-에폭시모르피난의 ６-아미도 유도체
CN105793421A (zh) 耐性突变型90kDa热休克蛋白质
US11773096B2 (en) Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same
CN121002029A (zh) 作为pkmyt1抑制剂的化合物
US9611276B2 (en) Imidazo bicyclic iminium compounds as antitumor agents
WO2013041859A1 (en) Cannabinoid-2-receptor agonists
WO2023044574A1 (en) Phosphorylated and sulfonated mescaline derivatives and methods of using
HK1207367B (en) Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
RU2800295C1 (ru) Оптически чистое оксаспиро-замещенное производное пирролопиразола, способ его получения и его фармацевтическое применение
WO2021155748A1 (en) Inhibitors of malarial and plasmodium falciparum hexose transporter and uses thereof
Tjin Mechanism-and Structure-Based Development of Small Molecule Inhibitors Against Therapeutically Important Enzymes
HK1224702A1 (en) Resistant mutant 90 kda heat shock protein

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired